Probi (STO:PROB) has signed a distribution agreement with Botanic Pharma, based in Casablanca, Morocco, for the distribution of Probi´s gut health product, Probi Digestis®. The Product will be launched in Morocco in Q1 2014 under the brand name I.B.S. Probi Digestis.
The gastrointestinal health market in Morocco is growing and sales are approximately 35 MEUR. I.B.S. Probi Digestis will be marketed by Botanic Pharma targeting GPs and Gastroenterologists as well as to consumers via retail drug stores and pharmacies.
“Botanic Pharma is a growing health care company in Morocco with a strong ambition to expand the business both nationally and in the MENA region. We are looking forward to work with Botanic Pharma and expand Probi´s business in the northern parts of Africa in the coming years,” said Gun-Britt Fransson, interim CEO of Probi.
“We are looking forward to launch I.B.S. Probi Digestis in our market. We strongly believe that the product will constitute an innovative, durable and efficient complement to people who are suffering from bloating, gas formation and pain”, said Amine Tahiri, CEO of Botanic Pharma.
I.B.S Probi Digestis is based on Lactobacillus plantarum 299v (DSM 9843), which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS. The product will be registered and launched based on Probi’s high quality probiotic ingredient.